Monograph
V08CA03 - Gadodiamide |
Not porphyrinogenic |
NP |
Rationale
Gadodiamide is excreted unchanged though the kidneys.
Chemical description
Gadodiamide is a nonionic gadolinium chelate.
Therapeutic characteristics
Gadodiamide is used as a magnetic resonance contrast medium. It is administered intravenously. Nausea is a common adverse reaction of gadodiamide that can be confused with an acute porphyric attack.
Hepatic exposure
Not relevant.
Metabolism and pharmacokinetics
Gadodiamide is rapidly distributed into extracellular fluid. About 96% of a dose is excreted unchanged in the urine within 24 hours. No metabolites have been found.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Drug reference publications | |
| 1. | Sweetman SC, editor. Martindale: The complete drug reference. Gadodiamide. Pharmaceutical Press 2009.
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Omniscan.
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Omniscan 
Omniscan 
Omniscan
© NAPOS 2025